Medicenna Therapeutics Corp. announced the appointment of Humphrey Gardner, M.D., as Chief Medical Officer (CMO) to lead the development strategy and execution of Medicenna?s clinical programs. Dr. Gardner?s career in the biopharmaceutical industry spans over two decades. Most recently, Dr. Gardner served as CMO at Harbour BioMed advancing novel antibody and bispecific therapeutics in oncology.

Previously, he was the CMO at Stingthera, CMO in Residence at Roivant Sciences and Chief of Medical Oncology at Evelo Biosciences, a Flagship Pioneering company. Prior to this, Dr. Gardner held senior roles at AstraZeneca as Clinical Vice President Translational Medicine, Oncology; Novartis as Executive Director, Oncology Translational Laboratories; and Biogen. Previously, in academia, Dr. Gardner was Assistant Professor at The Scripps Research Institute, Research Fellow at the Whitehead Institute at MIT and Clinical Fellow at Harvard Medical School, and he completed his internship at the Memorial University of Newfoundland.

Dr. Gardner is a Fellow of the College of American Pathologists and has authored nearly 100 publications. Dr. Gardner holds a bachelor?s degree in Biochemistry and his medical degree from the University of Cambridge.